Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain  by Giordano, Daniela et al.
Expression of cGMP-binding cGMP-speci¢c phosphodiesterase (PDE5)
in mouse tissues and cell lines using an antibody against the enzyme
amino-terminal domain
Daniela Giordano a, Maria Egle De Stefano a, Gennaro Citro b, Anna Modica c,
Mauro Giorgi c;*
a Dipartimento di Biologia Cellulare e dello Sviluppo, Universita' di Roma ‘La Sapienza’, Rome, Italy
b Laboratorio di Chemioterapia Sperimentale Preclinica, Istituto Regina Elena, Rome, Italy
c Dipartimento di Biologia di Base e Applicata, Universita' di l’Aquila, Via Vetoio, loc. Coppito, 67010 Coppito, L’Aquila, Italy
Received 12 June 2000; received in revised form 8 March 2001; accepted 8 March 2001
Abstract
We have produced a polyclonal antibody that specifically recognizes cGMP-binding cGMP-specific phosphodiesterase
(PDE5). The antibody was raised in rabbit using as immunogen a fusion protein, in which glutathione S-transferase was
coupled to a 171 amino acid polypeptide of the N-terminal region of bovine PDE5. The antibody is able to
immunoprecipitate PDE5 activity from mouse tissues and neuroblastoma extracts while it has no effect on all other PDE
isoforms present in the extracts. PDE5 activity recovered in the immunoprecipitates retains its sensitivity to specific inhibitors
such as zaprinast (IC50 = 0.6 WM) and sildenafil (IC50 = 3.5 nM). Bands of the expected molecular mass were revealed when
solubilized immunoprecipitates were analysed in Western blots. The antibody selectively stained cerebellar Purkinje
neurones, which are known to express high levels of PDE5 mRNA. Western blot analysis of mouse tissues revealed the
highest expression signal in mouse lung, followed by heart and cerebellum, while a lower signal was evident in brain, kidney
and a very low signal was present in the liver. In the hybrid neuroblastoma-glioma NG108-15 cells the antibody revealed a
high PDE5 induction after dibutyryl-cAMP treatment. ß 2001 Elsevier Science B.V. All rights reserved.
Keywords: Phosphodiesterase; Cyclic guanosine monophosphate; Phosphodiesterase-5 antibody; Glutathione S-transferase fusion pro-
tein; Murine neuroblastoma
1. Introduction
Cyclic nucleotide phosphodiesterases (PDE) are a
complex and expanding group of enzymes displaying
di¡erent substrate speci¢cities, kinetic and regulatory
properties and tissue-speci¢c distributions [1^4]. Re-
cently PDE11 has been described as the last member
of the known PDE family [5^7]. Whether each iso-
enzyme plays a speci¢c role in di¡erent cell types and
which role can be ascribed to speci¢c PDE isoforms
is still unclear, with a few exceptions, such as PDE6
in light transduction in the retina [8] and PDE3 in
insulin action and in the regulation of insulin secre-
tion [9].
PDE5 is a cGMP-speci¢c isoform, initially discov-
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ered in bovine lung and rat platelets [10,11] and later
found in several other tissues. Among these it has
been described in vascular smooth muscle cells,
where it plays a role in vascular relaxation mediated
by the NO/cGMP pathway [12,13]. This ¢nding has
led to the suggestion that it may be involved in male
erectile dysfunction and the PDE5 inhibitor sildena¢l
has recently been used in the treatment of this hu-
man disorder [14,15]. PDE5 has also been detected in
the superior cervical ganglion [16] and in the brain,
where its distribution appears to be con¢ned to spe-
ci¢c cellular components such as cerebellar Purkinje
cells [17,18]. This restricted distribution suggests a
possible role of the isoenzyme in speci¢c neuronal
populations. Although little is known about its spe-
ci¢c role in neuronal function and di¡erentiation, it
should be recalled that PDE5 has been related to
long-term depression (LTD) mediated by the NO/
cGMP pathway in Purkinje cells and striatal spiny
neurones [19,20].
PDE5 is a homodimer of two approx. 90^100 kDa
subunits, the monomer containing two allosteric
cGMP-binding sites whose function is not yet clear
[21,22]. Binding of cGMP to both allosteric sites
causes a conformational change in the enzyme, re-
sulting in the exposure of N-terminal protein kinase
(PK) G and PKA phosphorylation sites; although
early reports indicate that phosphorylation of the
puri¢ed enzyme had no e¡ect on its catalytic proper-
ties [23,24], induction of activity by PKA has been
observed in partially puri¢ed preparation of guinea
pig lung enzyme [25] and in cultured smooth muscle
cells [13]. PKA-PKG activation was recently ob-
served using recombinant bovine PDE5 enzyme
[26]. These data have raised questions concerning
of the role of phosphorylation as a regulatory mech-
anism of PDE5 activity in intact cells. Two small
putative PDE5 regulatory subunits of 14 and
18 kDa have recently been reported; they appear
structurally related to the PDE6 inhibitory Q subunit,
although their mechanism of action is still unclear
[27].
We have previously shown that cGMP PDE activ-
ity in two neuronal cell lines, mouse neuroblastoma
N18TG2 and the hybrid neuroblastoma-glioma
NG108-15, is due to the presence of PDE5; we
have also shown that PDE5 activity increases follow-
ing treatment of neuroblastoma cells with dibutyryl
(db)-cAMP [28]. Although a similar increase in en-
zyme activity has been observed in the two cell lines
studied (N18TG2 and NG108-15), enhanced gene ex-
pression was observed only in the hybrid NG108-15
cells, while no increase in PDE5 mRNA was found
in N18TG2 cells after dbcAMP treatment [29].
The complexity of PDE5 activity regulation, out-
lined above, underlies the need for a speci¢c anti-
body probe to evaluate the quantitative changes in
the expression of this enzyme at the protein level.
Here we describe the production and character-
ization of a speci¢c antibody raised against an N-
terminal PDE5 region which was used to analyse
the distribution of the enzyme in mouse tissues and
its regulation in neuroblastoma clones during di¡er-
entiation.
2. Materials and methods
2.1. Cell cultures
N18TG2, NG108-15 neuroblastoma cells and C6
glioblastoma cells were cultured as previously de-
scribed [28]. 5U105 cells were plated on 90 mm cul-
ture dishes (Falcon). Twenty-four hours after plat-
ing, the medium was replaced with DMEM
supplemented with either 10% FCS (control) or, for
treated cells, with 1% FCS and 5 mM dbcAMP (Sig-
ma, St. Louis, MO, USA) and changed after an addi-
tional 72 h. Five days after dbcAMP addition, both
control and treated cells were washed twice with PBS
and stored at 380‡C.
2.2. Enzyme extracts
Cells were collected by scraping at 4‡C in 20 mM
Tris-HCl bu¡er pH 7.2, containing 0.2 mM EGTA,
5 mM MgCl2, 1 mM PMSF, 5 mM L-mercaptoeth-
anol, 10 Wg/ml leupeptin, 5 Wg/ml bestatin, 10 Wg/ml
pepstatin A, and homogenized with 20 strokes in a
glass-te£on homogenizer. Homogenates were centri-
fuged at 100 000Ug for 45 min at 4‡C, the pellets
were resuspended in homogenization bu¡er and cen-
trifuged at 100 000Ug for 45 min; the ¢rst and sec-
ond supernatants were pooled. 0.1% Triton X-100
was included in the homogenization bu¡er in order
to ensure the recovery in the supernatants of mem-
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brane-associated PDE activity [28]. Tissue extracts
from bovine lung and from adult Swiss CD1 mice
were prepared following the procedure described for
cell extracts. Protein concentration was determined
as described by Bradford [30], using bovine serum
albumin (BSA) as standard.
2.3. Anion-exchange chromatography and FPLC gel
¢ltration
The enzyme extracts from each cell line were
loaded onto a Mono Q anion-exchange column
(HR 5/5, Pharmacia, Gaithersburg, MD, USA) in
an FPLC system (Pharmacia). The £ow rate was
adjusted to 0.5 ml/min and the absorbance of the
eluate monitored at 280 nm. Before loading the col-
umn was washed with bu¡er A (50 mM sodium ace-
tate, pH 6.5, containing 0.2 mM EGTA, 5 mM L-
mercaptoethanol, 0.1 mM PMSF, 5 mM NaF, 0.05%
Triton X-100), and washing with the same bu¡er was
continued for 10 min after loading the cell extract.
Elution was then performed with a linear gradient of
sodium acetate (0.05^1 M) in bu¡er B (sodium ace-
tate, pH 6.5, containing 0.2 mM EGTA, 5 mM L-
mercaptoethanol, 0.1 mM PMSF, 5 mM NaF, 0.05%
Triton X-100) over 20 min and 45 fractions of 0.5 ml
each were collected and assayed for PDE activity.
PDE activity recovered in the eluate ranged from
85 to 100%. Fractions corresponding to the peak of
PDE5 activity [28] were pooled and concentrated in a
Centricon 10 (Amicon, Danvers, MA, USA) in a
refrigerated centrifuge. This sample was loaded
onto an FPLC Superose 12 HR 10/30 column (Phar-
macia) and eluted at a £ow rate of 0.25 ml/min with
20 mM HEPES bu¡er, pH 7.0 (containing 1 mM
EGTA, 5 mM L-mercaptoethanol, 5 mM MgCl2,
100 mM NaCl, 2 mM PMSF, 0.05% Triton X-100).
Fractions with PDE activity were pooled, concen-
trated as described above and used for further anal-
ysis.
2.4. PDE isoforms preparation
Partially puri¢ed rat brain calcium-calmodulin
stimulated phosphodiesterase (PDE1) was obtained
in three chromatographic steps (DEAE-cellulose fol-
lowed by CaM agarose a⁄nity column and gel ¢ltra-
tion) as already described [31]. This procedure gives
an enzyme preparation showing a 6-fold stimulation
of cGMP hydrolytic activity in the presence of
0.1 mM calcium and 3 Wg/ml calmodulin. A partial
puri¢cation of rat liver PDE2 activity was obtain-
ed in three chromatographic steps (DEAE-cellu-
lose followed by ammonium sulphate precipita-
tion and gel ¢ltration) according to Yamamoto et
al. [32]; this preparation showed a 5-fold stimu-
lation of cAMP hydrolytic activity in the presence
of 1 WM cGMP. A partial puri¢cation of PDE6
was obtained by anion exchange chromatog-
raphy and gel ¢ltration according to Baehr et al.
[33].
2.5. PDE assay
PDE activity was determined following the two-
step method described by Thompson and Appleman
[34], in a ¢nal volume of 0.3 ml of assay bu¡er (60
mM HEPES pH 7.2, 0.1 mM EGTA, 5 mM MgCl2,
0.5 mg/ml BSA, 30 Wg/ml soybean trypsin inhibitor)
using [3H]cyclic GMP (speci¢c activity 16.8 Ci/mmol)
or [3H]cyclic AMP (speci¢c activity 28 Ci/mmol)
(Amersham, Buckinghamshire, UK) as a substrate
at a ¢nal concentration of 1 WM.
2.6. Production and puri¢cation of a
PDE5-glutathione S-transferase fusion
protein for immunization
A speci¢c PDE5 antiserum was produced using as
immunogen a fusion protein containing glutathione
S-transferase (GST) and a 171 amino acid peptide
corresponding to the 68^239 amino acid residues of
the N-terminal bovine lung PDE5 sequence [35]. The
fusion protein was obtained as follows.
RT-PCR ampli¢cation was performed on bovine
lung poly(A)RNA (0.3 Wg). Thirty-¢ve PCR cycles
were performed on cDNA after an initial denaturing
step of 10 min at 91‡C using the following pro¢le:
91‡C for 1 min; 52‡C for 1 min; 72‡C for 2 min
using an oligonucleotide sense (5P-AGG GAT CCA
ATC CTG CTC TTG CCC CTT GCAG-3P ; nucleo-
tides (nt) 298^320, with BamHI site added on 5P) and
antisense primer (5P-GAG GAT CCT CAT AGG
CGT CTT TGA TGT TC-3P ; nt 788^816, with Bam-
HI site included). The 517 nucleotide fragment ob-
tained was then inserted into pGEX-3X vector
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(Pharmacia Biotech) in frame with the GST gene
present in the vector and cloned into DH5K bacteria
[36,29]. One of the clones transfected with pGEX-3X
containing the construct was stimulated for 3 h with
1 mM IPTG and the bacterial proteins were ex-
tracted by sonication of bacteria pellets resuspended
in PBS (containing 1% Triton X-100, antipain 2 Wg/
ml, pepstatin 2 Wg/ml, aprotinin 10 Wg/ml, leupeptin
20 Wg/ml). The supernatant obtained after 10 min
centrifugation at 12 000Ug at 4‡C was ¢ltered (0.45
Wm) and loaded onto a glutathione-agarose column
(Pharmacia Biotech), previously washed with PBS
and equilibrated with PBS+1% Triton X-100 (4‡C).
After a wash with PBS, the GST-PDE5 fusion pro-
tein was eluted with 5 mM glutathione (Sigma) in 50
mM Tris-HCl, pH 8. Fractions obtained from the
a⁄nity chromatography were analysed by SDS-
PAGE to verify the presence of the puri¢ed GST-
PDE5 protein at the predicted molecular mass posi-
tion (45.3 kDa). The puri¢ed product was then in-
jected into a rabbit, following standard immuniza-
tion procedures. Antiserum was collected and an
anti-PDE5 antibody IgG fraction was puri¢ed by
a⁄nity chromatography on a protein A column
(Amersham Pharmacia Biotech). The IgG fraction
was eluted with 0.1 M glycine-HCl bu¡er, pH 3.0.
The eluate was neutralized immediately with 1 M
Tris-HCl, pH 8, and stored at 320‡C until use.
Pure GST peptide (26 kDa) was obtained by cloning
pGEX-3X into DH5K bacteria and using the same
‘in vitro’ expression and puri¢cation procedure de-
scribed for the fusion protein.
2.7. Immunoprecipitation
Sepharose CL-4B-protein-A resin (Pharmacia) was
washed twice with Tris bu¡er saline (TBS) contain-
ing 0.1% BSA; 50 Wl aliquots were incubated with
increasing concentrations (2.4 ng^0.9 mg/ml) of
PDE5 IgG fraction in a ¢nal volume of 0.3 ml. After
1^2 h at 25‡C, the unbound antibody was removed
by two washes in TBS/0.1% BSA. Aliquots of
N18TG2 cells and mouse tissue were added and the
mix (¢nal volume of 0.5 ml) incubated for 2 h at
25‡C in a rotating shaker. Following centrifugation
of the mix, pellets containing immunoadsorbed pro-
teins were ¢rst washed and then resuspended in TBS.
Both supernatant and resuspended pellets were as-
sayed for PDE activity in the absence and in the
presence of PDE5-speci¢c inhibitors. The same pro-
tocol using 0.9 mg/ml PDE5 IgG was used for im-
munoprecipitation of a mix of mouse tissue extracts.
Control experiments were performed by replacing
PDE IgG fraction with a non-immune IgG rabbit
fraction (data not shown): in this case no PDE ac-
tivity was detected in the pellet.
2.8. Western blot analysis
All samples analysed in Western blot were dena-
tured with SDS-PAGE sample bu¡er (60 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercapto-
ethanol, 0.0025% bromophenol blue), boiled and
subjected to electrophoresis on an 8% SDS-poly-
acrylamide gel (SDS-PAGE) and then blotted on-
to nitrocellulose membranes (Protran, Schleicherp
Schuell). Western blot analysis was performed by
incubating the blots for 3 h with the anti-PDE5
antibody at a 1/2000 dilution; in some cases compe-
tition was performed by adding 10 Wg/ml of GST-
PDE5 or GST peptide together with the antibody.
In one experiment an anti-GST antibody (Pharmacia
Biotech) was used. A secondary anti-rabbit IgG
alkaline phosphatase conjugated antibody was used
to reveal the immunocomplexes and the bands
stained with NBT (nitro blue tetrazolium) in the
presence of BCIP (5-bromo-4-chloro-3-indolyl phos-
phate).
2.9. Immunocytochemistry
Two adult female mice (Strain CD1) were deeply
anaesthetized with an i.p. injection of sodium pento-
barbital (Pentothal Sodium, Farmaceutici Gellini,
Aprilia, LT, Italy) and perfused transcardially with
200 ml of an oxygenated Ringer’s solution, pH 7.3,
followed by 500 ml of 4% (w/v) freshly made depoly-
merized paraformaldehyde in 0.1 M sodium phos-
phate bu¡er (PB), pH 7.4. The brains were dissected
1 h after termination of the perfusion and cryopro-
tected for 72 h in 30% (w/v) sucrose in saline, until
they sank. Serial sagittal sections (25 Wm thick) were
cut on a cryostat and collected free £oating in 0.5 M
Tris-HCl, pH 7.6. The sections were incubated with
10% (v/v) methanol and 3% (v/v) H2O2 in 0.5 M
Tris-HCl to inactivate endogenous peroxidases,
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rinsed thoroughly in bu¡er, and blocked for 1 h in
5% (w/v) dry defatted milk and 0.5% Triton X-100 in
Tris-HCl. The slices were incubated for 36 h at 4‡C
with the PDE5 antibody, diluted 1/400 in 0.5 M Tris-
HCl containing 1% (w/v) dry milk and 0.2% Triton
X-100. Following several rinses with bu¡er, the sec-
tions were incubated for 1 h at room temperature
(RT) with 1:300 goat anti-rabbit IgG (Sternberger
Monoclonal, Baltimore, MD, USA), rinsed again
and incubated for 1 h at RT in 1:1000 rabbit per-
oxidase-anti-peroxidase (Sternberger Monoclonal).
Finally, the sections were rinsed in Tris-HCl and
antibody-binding sites were revealed by incubating
with 0.05% DAB (3,3P-diaminobenzidine tetrahydro-
chloride, Sigma) and 0.01% H2O2 in Tris-HCl. Fol-
lowing thorough rinsing in bu¡er, the sections were
dry mounted with cresyl gel (0.1% w/v gelatin in 80%
v/v ethyl alcohol) and coverslipped with Eukitt bal-
sam. Control sections, obtained either by omitting
the primary antibody or by incubating with the
PDE5 antibody preadsorbed with 150 Wg/ml of the
GST-peptide overnight at 4‡C, were free of the im-
munoreaction product.
3. Results
3.1. Production and characterization of
a PDE5-speci¢c antiserum
To obtain a PDE5-speci¢c antiserum, a PDE5-
GST fusion protein was produced, puri¢ed and
used as an immunogen in rabbits as described in
Section 2. The 171 amino acid PDE5 peptide used
was selected in the amino-terminal region of the pro-
tein for its divergence from other PDEs. A sequence
comparison between this peptide and all SwissProt
database using the FASTA3.3 program gave a 91^
94% identity only with cloned (human, dog, rat)
PDE5 isoforms. Low and scattered identity was
found for PDE6 (18^19% considering human, bovine
and mouse isoforms) and PDE2 isoforms (20.9^
21.5% considering bovine, rat and human isoforms).
The presence of speci¢c PDE5 antibodies in the
IgG fraction was investigated in an immunoprecipi-
tation assay on neuroblastoma cell extracts. Fig. 1A
shows that the antibody precipitates PDE5 activity
present in N18TG2 extracts in a concentration-de-
Fig. 1. Immunoprecipitation of PDE5 activity. Samples of N18TG2 cell extracts were incubated as described in Section 2 with increas-
ing concentrations of PDE5 antibody (2.4, 7.4, 11.5, 23, 46, 92, 185, 370 and 600 ng/ml of IgG) (A) After centrifugation, cGMP PDE
activity was measured in the supernatants (b) and in the pellets (8). cAMP PDE activity in the same cell extracts was also measured
in the supernatants (E). Calculated S.D. was in all cases 6 5% of the reported values. (B) The solubilized pellets were subjected to
Western blot using the PDE5 antibody; lanes 1^9: from 2.4 to 600 ng/ml; in lane C supernatant of a N18TG2 cell extract loaded as
control.
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pendent manner. It also shows that the activity lost
in the extracts subjected to immunoprecipitation is
recovered in the pellet. On the other hand, cAMP
PDE activity present in the N18TG2 extract, previ-
ously characterized as PDE4 [37], is not immunopre-
cipitated. When the immunoprecipitates were ana-
lysed by Western blot, one major band of 98 kDa
and two minor bands of 93 and 86 kDa were re-
vealed; their intensity is dependent on the concentra-
tion of the antibody (Fig. 1B). Inhibition studies
were also performed on the immunoprecipitated
N18TG2 PDE activity using the PDE5-speci¢c inhib-
itors zaprinast and sildena¢l (Fig. 2); the calculated
IC50 values were distinctive of PDE5 isoforms
(3.5 nM for sildena¢l and 0.6 WM for zaprinast)
[22]. To verify the speci¢city of antibody with respect
to other PDEs we performed similar experiments us-
ing a mix of mouse tissue extracts containing the
majority of PDE isoforms, including PDE2 (liver)
and PDE6 (retina). The inhibition of PDE activity
recovered in the resuspended pellet is reported in Fig.
2 and shows an IC50 (5 nM for sildena¢l and 1 WM
for zaprinast) very close to that obtained for
N18TG2 immunoprecipitated activity. On the other
hand, the Western blot analysis shown in Fig. 3 dem-
onstrates a very low level of immunoreactivity for
the PDE5 antibody and PDE1, PDE2 and PDE6
isoforms. The speci¢city of the antibody for PDE5
is further con¢rmed by Western blot analysis of
N18TG2 cell extracts subjected to successive steps
of puri¢cation, as indicated in Section 2. Crude ex-
tracts and eluates from Mono Q anion-exchange
chromatography and FPLC gel ¢ltration were ana-
lysed (Fig. 4). When enriched preparations of PDE5
from N18TG2 and NG108-15 (lanes 1, 2 and 3) were
loaded onto the gel, the staining intensity of immu-
noreactive bands paralleled the speci¢c activity of the
preparations (Table 1). It is interesting to note that,
unlike the immunoprecipitates shown in Fig. 2, in
N18TG2 crude and partially puri¢ed PDE5 prepara-
tions the intensity of the 98 and 86 kDa bands is
almost the same while in the NG108-15 clone the
two bands were not evident in the crude extract. In
both neuroblastoma clones the 93 kDa band was not
revealed. The speci¢city of the antiserum for PDE5
protein was ¢nally shown by the lack of immuno-
reaction in C6 glioma cell extracts (Fig. 4) which
only express PDE1 and PDE4 enzymes [38] and by
peptide competition studies of Fig. 5 showing a
Western blot analysis of N18TG2 in NG108-15 ex-
tracts in the presence and absence of peptide used as
immunogen. This blot was overexposed to show un-
speci¢c low molecular mass bands. On the other
hand, the antibody did not reveal any band in West-
ern blot when GST protein alone was loaded onto
the gel as shown in Fig. 6; GST and GST-PDE5
peptides are, however, strongly recognized by an
anti-GST antibody. Lastly, the speci¢city of the anti-
body is further con¢rmed by immunocytochemistry
of cerebellum sections showing that immunostaining
is restricted to Purkinje cell bodies (Fig. 7A^C), as
previously described in rat by in situ hybridization
Fig. 3. Speci¢city of PDE5 antibody. Western blot analysis
with PDE5 antibody; 50 Wg of proteins were loaded in each
lane. Lanes: A, N18TG2 cell extract used as control; B, rat liv-
er PDE2; C, PDE6 from rat retina; D, rat brain PDE1. (For
preparation see Section 2.)
Fig. 2. Inhibition analysis of immunoprecipitated PDE5 activ-
ity. Inhibition by zaprinast (R,O) and sildena¢l (F,E) of PDE5
immunoprecipitated from N18TG2 cell (R,F) and a mix of
mouse lung, brain, kidney, retina, and liver extracts (O,E).
PDE activity was assayed with 1 WM cGMP as substrate.
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[39]. Immunostaining of Purkinje cells is abolished
by omitting the primary antibody or by antibody
preadsorbtion, as described in Section 2 (Fig. 7D).
3.2. PDE5 expression in mouse tissues
We used the antibody to analyse the distribution
of PDE5 in several mouse tissues by Western blot.
As shown in Fig. 8A, three immunoreactive bands
(approx. 98, 93 and 86 kDa) were detected by the
antibody as described above for neuroblastoma cell
immunoprecipitates. A major band of about 98 kDa
is highly expressed, mainly in mouse lung, but also in
the cerebellum and heart; it shows a lower level of
expression in the brain, excluding the cerebellum,
and an intermediate level in the kidney, while it is
not detectable in the liver. The other two bands show
a weaker expression: in all cases the 93 kDa band is
present in the lung and cerebellum, and a lower level
can also be seen in the liver, brain and heart. The 86
kDa band is evident in the lung; it can be observed
at lower levels in the heart, cerebellum, brain and
kidney. The speci¢city of all three bands is demon-
strated by their absence when GST-PDE5 peptide
was added together with the antibody (Fig. 8B); on
the other hand, the three bands persisted in the pres-
ence of pure GST, which was unable to compete with
the antibody (not shown).
3.3. PDE5 expression during neuroblastoma cell
di¡erentiation
We used PDE5 antibody for Western blot analysis
Fig. 6. PDE5 antibody speci¢cities. SDS-PAGE of 10 Wg of
GST-PDE5 peptide (lane 1) and 6 Wg of pure GST peptide
(lane 2). (A) Coomassie blue stain; (B) Western blot using
PDE5 antibody; (C) Western blot using an anti-GST antibody.
Fig. 5. Peptide competition study. Samples (50 Wg of total pro-
tein) of N18TG2 and NG108-15 extracts were loaded in each
lane and analysed by Western blot with PDE5 antibody in the
presence and absence of 10 Wg/ml of peptide. To reveal unspe-
ci¢c low molecular mass bands the blots are overstained with
alkaline phosphatase detection solution.
Fig. 4. PDE5 in neuroblastoma cells at successive puri¢cation steps. 20 Wg of protein from N18TG2 and NG108-15 cell extracts and
eluates of the indicated chromatographic columns were analysed by Western blot. Lanes: 1, cell extracts; 2, Mono Q anion-exchange
chromatography; 3, FPLC gel ¢ltration. 100 Wg of bovine lung (BL) and rat glioma C6 (C6) were used respectively as positive and
negative standards.
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Fig. 7. PDE5 immunocytochemistry on sagittal sections of rat cerebellum. Immunoreactivity for PDE5 strongly labels Purkinje cell
bodies (A^C) and dendrinites (B,C). Arrowheads in C point to the dendritic arborization of a Purkinje cell. (D) Control section ob-
tained by preabsorption of the primary antibody with the GST^PDE5 peptide. A: U60; B,D: U240; C: U620.
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of neuroblastoma clone extracts, to establish whether
the level of the protein would con¢rm the data on
the expression of PDE5 mRNA during di¡erentia-
tion [29]. The upper panel of Fig. 9 shows a repre-
sentative Western blot analysis of N18TG2 and
NG108-15 cell extracts under basal conditions and
after 5 days of dbcAMP treatment. The level of the
protein appears to be higher under di¡erentiating
conditions only in the hybrid clone, while in
N18TG2 cells no signi¢cant change in the level of
the protein can be observed. The lower panel of
Fig. 9 (right side) shows densitometric analysis of
the immunoreactive bands revealed in many di¡erent
blots; the left side shows PDE5 activity assayed
in the same experiments. While these data con¢rm
that in NG108-15 cells the increase in PDE5 ac-
tivity is related to an enhanced expression of the
protein, they de¢nitely show that, in N18TG2 cells,
a higher level of PDE5 activity does not depend
on a higher level of the enzymatic protein in the
cells. Mechanisms other than upregulation of
the protein expression must be operating in this
case.
4. Discussion
In order to investigate PDE5 distribution in mouse
tissue and the regulation of its expression in mouse
neuroblastoma lines, we raised a polyclonal antise-
rum in rabbit, using as immunogen the N-terminal
domain of the enzyme. Because of its low homology
with other PDEs the N-terminal sequence seemed the
most suitable to produce a PDE5-speci¢c antiserum.
This is because the peptide produced in the bacterial
expression system corresponds to a unique regulatory
region of the enzyme and overlaps with only a minor
portion of one of the cGMP-binding tandem repeat
sequences which are also found in PDE2 and PDE3
[35]. The speci¢city of the antibody obtained was
demonstrated by several ¢ndings: (1) the decrease
in cGMP hydrolytic activity in the supernatant of
the N18TG2 extract in immunoprecipitation assays
and the recovery of this activity in the immunopre-
cipitated pellets with inhibition properties speci¢c to
the PDE5 isoform; (2) the increase in PDE5 immu-
noreactive bands corresponding with the increase in
PDE5-speci¢c activity following N18TG2 chromato-
Fig. 8. PDE5 expression in mouse tissues. Western blot analysis was performed by loading in each lane 100 Wg of protein from the in-
dicated tissue extracts. On the right molecular masses (kDa) of the revealed bands are indicated. (A) Bovine lung (BL); mouse lung
(Lu), brain (Br), cerebellum (Ce), heart (He), liver (Li), kidney (Ki). (B) Competition analysis using GST-PDE5 peptide (see Section
2) in mouse lung (Lu) and cerebellum extracts (Ce). The three speci¢c bands are abolished by 10 Wg/ml peptide.
Table 1
Partial puri¢cation of PDE5 from neuroblastoma cell extracts
Puri¢cation step N18TG2a NG108-15b
Total activity
(nmol/min)
Speci¢c activity
(nmol/min/mg)
Puri¢cation
(fold)
Total activity
(nmol/min)
Speci¢c activity
(nmol/min/mg)
Puri¢cation
(fold)
Cell extract 3.14 0.15 1.9 0.19
Mono Q FPLC
chromatography
1.8 0.36 2.3 0.31 0.64 3.4
FPLC gel ¢ltration 0.82 0.61 3.86 0.16 1.44 7.6
PDE assays were performed at 1 WM cGMP as substrate. This puri¢cation scheme is typical of one performed at least three times.
aN18TG2 control cells.
bNG108-15 di¡erentiated cells.
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graphic puri¢cation steps; (3) the immunostaining of
PDE5 in the cerebellum, showing strong and selec-
tive immunoreactivity in Purkinje cells, which coin-
cides with the reported PDE5 mRNA localization
[17]. Furthermore, using a mixture of mouse tissue
extracts in which most PDE isoforms and splice var-
iants are present, the antibody in question can
immunoprecipitate cGMP-PDE activity with inhibi-
tion features speci¢c to PDE5. Moreover, although
a chimerically joined GST peptide was present in
the peptide used as immunogen, our experiment
produced no evidence of cross-reactivity with GST
alone. Finally, the antibody showed a very low level
of immunoreactivity with other PDEs. These ¢nd-
ing prove that our antibody does not signi¢cantly
recognize other phosphodiesterase isoforms besides
PDE5.
The tissue distribution of PDE5 reported in Fig. 8
largely con¢rms data reported for human and rat
tissue by Northern blot analysis [17,18,40,41] show-
ing the highest expression in the lung; relatively high
expression is also found in the cerebellum and heart
and low expression in the liver and kidney. In addi-
tion to the 98 and 93 kDa bands, corresponding to
the molecular masses of PDE5A1 and PDE5A2 re-
spectively, a third band of approx. 86 kDa is re-
vealed in all cases. This would appear to be a speci¢c
PDE5 signal, since it disappears when the antigen
peptide is added to the antibody. At least two splice
variants of mRNA, corresponding to PDE5A1 and
PDE5A2, have been reported in human tissues [18].
The 86 kDa band may represent an additional splice
variant, not yet described; alternatively, it may result
from protein modi¢cation(s) undetectable in previous
studies of mRNA distribution. The reported presence
of a myristylation site in PDE5A1 [39] may be an
example of such modi¢cations.
With regard to the neuroblastoma lines we con-
¢rmed that the induction of PDE5 activity by
cAMP occurs via two di¡erent mechanisms, as pre-
Fig. 9. Western blot analysis of PDE5 expression during neuroblastoma cell di¡erentiation. (Upper panel) Representative Western
blot of PDE5 bands revealed in dbcAMP treated (Di¡) and control (Ctrl) neuroblastoma cell extracts using PDE5 antibody. 50 Wg of
protein were loaded in each lane. (Lower panel) Comparison in the control (C) and dbcAMP treated (D) neuroblastoma cell lines of
cGMP-PDE activity and densitometric analysis of immunostained bands. PDE activity histograms are the mean of six observations
( þ S.E.). Histograms of immunostained bands represent the mean values ( þ S.E.) of ¢ve di¡erent experiments.
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viously suggested by Northern blot analysis [28]. The
constant intensity of the bands in N18TG2 cells after
cAMP treatment indicates that in this case a more
complex regulatory system is activated than in
NG108-15. As noted, the phosphorylation state of
the protein is dependent on cGMP binding to the
allosteric enzyme site and this PKG-dependent phos-
phorylation causes an increase in catalytic activity
[13,26]. On the other hand, in airway smooth muscle
cells a PKA-dependent phosphorylation of PDE5 has
been shown to be prevented by the PDE6Q inhibitory
subunit. Two small proteins, immunologically related
to PDE6Q, have been found associated with PDE5 in
these cells and have been proposed as a possible
regulatory mechanism for PDE5 [27]. A similar sys-
tem may be responsible for the induction of PDE5
activity in N18TG2 cells, when they are exposed
to dbcAMP treatment, with a consequent activation
of PKA-mediated phosphorylation of the enzyme.
Although further work is needed to clarify whether
this regulation system is present in N18TG2, the data
presented here clearly show that the two cell lines
follow di¡erent pathways for the regulation of
PDE5 activity.
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